Disease · MONDO_0013600
Comparisons in its trials65
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 65
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Circadin vs Placebo: serious adverse events | 1 of 394 | 3 of 395 | 789 | NCT00397189 | Trial comparisons |
| Suvorexant vs Placebo: Number of Participants Who Reported Suicidal Ideation and/or Behavior On Study Based on Responses to the Columbia Suicide Severity Rating Scale (C-SSRS) | 6 of 521 | 0 of 258 | 779 | NCT01021813 | Trial comparisons |
| Esmirtazapine 4.5 mg vs Placebo: Number of Participants Who Experienced Adverse Events (AEs) | 253 of 342 | 75 of 115 | 457 | NCT00631657 | Trial comparisons |
| Esmirtazapine 4.5 mg vs Placebo: Number of Participants Who Discontinued Study Drug Due to an AE | 47 of 342 | 7 of 115 | 457 | NCT00631657 | Trial comparisons |
| Esmirtazapine 4.5 mg vs Placebo: serious adverse events | 8 of 342 | 2 of 115 | 457 | NCT00631657 | Trial comparisons |
| Tasimelteon vs Placebo: deaths from any cause | 0 of 160 | 0 of 160 | 320 | NCT03373201 | Trial comparisons |
| Tasimelteon vs Placebo: serious adverse events | 1 of 160 | 0 of 160 | 320 | NCT03373201 | Trial comparisons |
| Zolpidem 3.5 mg vs Placebo: serious adverse events | 0 of 150 | 0 of 145 | 295 | NCT00466193 | Trial comparisons |
| Suvorexant vs Placebo: deaths from any cause | 0 of 142 | 0 of 143 | 285 | NCT02750306 | Trial comparisons |
| Suvorexant vs Placebo: serious adverse events | 1 of 142 | 0 of 143 | 285 | NCT02750306 | Trial comparisons |
| Esmirtazapine 1.5 mg vs Esmirtazapine 3.0 mg: Number of Participants Who Discontinue Study Drug Due to an AE | 21 of 128 | 24 of 131 | 259 | NCT00561574 | Trial comparisons |
| Esmirtazapine 1.5 mg vs Esmirtazapine 3.0 mg: Number of Participants Who Experience at Least One Adverse Event (AE) | 115 of 128 | 116 of 131 | 259 | NCT00561574 | Trial comparisons |
| Esmirtazapine 1.5 mg vs Esmirtazapine 3.0 mg: serious adverse events | 9 of 128 | 6 of 131 | 259 | NCT00561574 | Trial comparisons |
| Ramelteon 4 mg QD vs Placebo QD: serious adverse events | 0 of 130 | 0 of 129 | 259 | NCT00756002 | Trial comparisons |
| Eye Mask and Ear Plugs vs Control: Use of Zopiclone (Night Sedation) | 3 of 109 | 2 of 97 | 206 | NCT02732912 | Trial comparisons |
| Eye Mask and Ear Plugs vs Control: Number of Falls | 0 of 109 | 0 of 97 | 206 | NCT02732912 | Trial comparisons |
| Eye Mask and Ear Plugs vs Control: deaths from any cause | 0 of 109 | 0 of 97 | 206 | NCT02732912 | Trial comparisons |
| Eye Mask and Ear Plugs vs Control: serious adverse events | 0 of 109 | 0 of 97 | 206 | NCT02732912 | Trial comparisons |
| Defined CBD vs Placebo: deaths from any cause | 0 of 99 | 0 of 88 | 187 | NCT05233761 | Trial comparisons |
| Defined CBD vs Placebo: serious adverse events | 0 of 99 | 0 of 88 | 187 | NCT05233761 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0013600/comparisons